Obermatt
See Similar Stocks →

Champions Oncology

NAQ:CSBR · US15870P3073
Life Sciences Tools & ServicesSmall

360

32
Medium confidence — indicative
Profit price91
Owner Earnings Yield1
Dividend Yield1
Price/Sales75
EV / Gross Profit87
Price/Book6
Return on Capital22
Cash Return on Capital10
Return on Equity20
EBIT Margin45
Gross Profitability100
Accruals83
Owner Earnings Margin61
Sales growth20
Profit Growth3
Long-Term EPS Growth6
Owner Earnings Growth7
Reinvestment11
Price momentum27
Debt load32
Refinancing13
Debt Payback1
Liquidity12
Analyst ratings100
Expectations trend2
Market mood51
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Champions Oncology doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Founded1985
Employees167
Websitechampionsoncology.com
ISINUS15870P3073
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Health DiagnosticsOncologyGeneticsBiotechnologyHealth Care

Description

Champions Oncology, Inc. (Champions), a technology-enabled research organization, engages in creating technology solutions to be utilized in drug discovery and development. The company's research center operates in both regulatory and non-regulatory…

Analysis

Middle-of-the-road

Champions Oncology, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is stretched. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
1
2023202420252026

All-time high

54

Jan 2025

All-time low

1

Jun 2026

Average rank

20

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
75
64
87
93
Price/Earnings
38
23
1
24
Price/Book
6
1
1
1
Dividend Yield
1
1
1
1
Value (overall)
25
10
42
37

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Champions Oncology with its peers
Tempus AI
NSQ:TEM
28
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Charles River Laboratories
NYQ:CRL
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Inotiv
NAQ:NOTV
16
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Personalis
NMQ:PSNL
8
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Cytek Biosciences
NSQ:CTKB
38
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
MaxCyte
NSQ:MXCT
17
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →